Shield Therapeutics (STU:1JS) Institutional Ownership: 0.96% (As of Jul. 06, 2026)


What is Shield Therapeutics Institutional Ownership?

Shield Therapeutics STU:1JS Institutional Ownership is 0.96% as of Jul. 06, 2026. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Shield Therapeutics's institutional ownership is 0.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Shield Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Shield Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Shield Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Institutional Ownership Chart

Shield Therapeutics Historical Data

The historical data trend for Shield Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.62 0.62 0.96 1.01 1.11 0.96 0.96 0.96 0.96 0.96

Shield Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.96% mean?
Shield Therapeutics (STU:1JS) has a Institutional Ownership of 0.96% as of Jul. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Institutional Ownership too high?
Shield Therapeutics' current Institutional Ownership is 0.96%.
How does Shield Therapeutics' Institutional Ownership compare to ZTS and UTHR?
Shield Therapeutics' Institutional Ownership of 0.96% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Institutional Ownership is 0.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Institutional Ownership is 0.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Institutional Ownership is 0.96% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.